Brokers Issue Forecasts for ANRO Q1 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities researchers at William Blair issued their Q1 2026 EPS estimates for shares of Alto Neuroscience in a research note issued to investors on Friday, March 21st. William Blair analyst M. Minter forecasts that the company will earn ($0.53) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.09.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO opened at $2.65 on Monday. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $3.60 and its two-hundred day moving average is $5.98. The firm has a market capitalization of $71.34 million and a P/E ratio of -1.04. Alto Neuroscience has a 52 week low of $2.58 and a 52 week high of $18.35.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Alto Neuroscience by 182.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after buying an additional 120,779 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Alto Neuroscience by 84.5% during the third quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock valued at $753,000 after purchasing an additional 30,135 shares during the last quarter. FMR LLC grew its position in Alto Neuroscience by 1.4% in the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after buying an additional 32,040 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after buying an additional 3,715 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in shares of Alto Neuroscience during the 3rd quarter valued at $146,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.